Johnson & Johnson Reports Promising Phase 1 Results For Erda-iDRS In Early-Stage Bladder Cancer
(RTTNews) – Johnson & Johnson (JNJ) announced new data from an open-label, multicenter Phase 1 study evaluating Erda-iDRS, an investigational intravesical drug-releasing system with erdafitinib, in patients with non-muscle-invasive bladder cancer (NMIBC) harboring select FGFR alterations. Results were presented at the European Association of Urology (EAU) 2026 Annual Meeting. FGFR alterations occur in approximately 70%…

